
Scientists recover proteins from a 24 million-year-old rhino fossil. Are dinosaurs next?
The 24 million-year-old tooth, which was unearthed in the Canadian Arctic, contains proteins that are 10 times older than the most ancient known DNA. Using the sample, scientists have now analyzed the oldest detailed protein sequence on record.
'Enamel is so hard it protects these proteins over deep time (long time scales),' said Ryan Sinclair Paterson, a postdoctoral researcher at the Globe Institute at the University of Copenhagen in Denmark who led the Canadian research. 'It's essentially like a vault. What we did was unlock this vault, at least for this specific fossil.'
The study of ancient DNA preserved in bones, fossils and dirt has revolutionized archaeological science, pulling back the curtain on lost empires, mysterious clans, ice age creatures and previously unknown human species. Ancient proteins promise a similar revolution for fossils that are many millions of years old and currently beyond the chronological reach of ancient DNA.
The study, which published July 9 in the scientific journal Nature, showcases the enormous potential of the field, known as paleoproteomics.
Proteins, which are made up of sequences of amino acids, are more robust than DNA, a fragile molecule that degrades relatively easily. Although proteins contain less detailed information, they can help to elucidate a specimen's evolutionary history, diet, even in some cases the sex of a fossil.
'The next step is to demonstrate that it's not just one sample, one lucky strike,' said coauthor Enrico Cappellini, a professor at the University of Copenhagen's Globe Institute who has pioneered methods to extricate proteins from fossils and was involved in the Canadian research.
'But potentially there's a huge area of research that could be further clarified and then, if we really push it farther … we could even start to investigate dinosaurs,' he added.
Cappellini and Paterson, along with colleagues at the University of York and the Canadian Museum of Nature, recovered sequences from seven proteins preserved inside the fossilized rhino tooth.
Sequencing ancient proteins involves determining the order of amino acids in a sample. By comparing the sequences with those of living and extinct relatives, the scientists were able to glean information about the evolution of the rhino. The analysis revealed that it diverged from the same family as living rhinos about 41 million to 25 million years ago.
'In the fossil record, there were some crazy forms (of rhinoceros species). There's the woolly rhinoceros, and maybe you've heard of the Siberian unicorn with the gigantic horn,' Paterson said. 'What we were able to do is compare our mystery rhino with other forms and find out where it falls in the family tree.'
Separate research, also published July 9 in the journal Nature, which sampled fossils from Kenya's Turkana Basin, suggests that biomolecules can survive for millions of years, even in searing, tropical environments.
The study, which analyzed 10 mammal fossils, including the relatives of today's elephants, hippos and rhinos, was published by researchers at the Smithsonian Institution's Museum Conservation Institute and Harvard University.
They recovered proteins from five of the fossils dated 1.5 million to 18 million years ago, and found that even in tropical regions with high temperatures scientists can extract prehistoric proteins, which can reveal links between ancient elephants and rhinos and their modern-day relatives.
While the information contained in the Kenyan proteins wasn't as detailed as that found in the Canadian fossil, the authors said that their presence within enamel tissues in one of the world's warmest regions holds promise that proteins in much older fossils could be discovered.
'We were excitingly successful. We went back to about 18 million years. I think going back in time should be possible,' said study author Timothy Cleland, a physical scientist at the Museum Conservation Institute.
The research on the Canadian fossil was 'sound and super interesting,' said Maarten Dhaenens, a researcher at the University of Ghent in Belgium who specializes in proteomics. However, Dhaenens, who wasn't involved in either study, said the methodology used on the Kenyan fossils was complex and less tested. The researchers' findings, he argued, are harder to interpret and warranted a more thorough assessment.
'The data is publicly available, so we should be able to verify their claims through manual validation, but this takes time,' he said via email.
Evan Saitta, paleontologist and research associate at Chicago's Field Museum of Natural History, said it was 'shocking' to find proteins preserved within fossils at tropical latitudes and added that the findings needed replication. It had been previously assumed that cold temperatures were necessary to slow down the breakdown of proteins.
'If that is a true result … it should be very easy to replicate,' he noted. 'We should be able to go around all different fossil sites all over the world and find enamel peptides (proteins).'
Getting proteins from fossils this old would be a palaeontologist's dream come true, said Matthew Collins, the McDonald Professor in Palaeoproteomics at the UK's University of Cambridge, who agreed that the research on the Canadian fossil was more convincing. Collins, like Saitta, was not involved in the new research.
'This is amazing. It's really exciting, but at the same time I've been disappointed so much in my career by thinking that we had very old proteins and we didn't,' added Collins, who has tried to recover proteins from dinosaur fossils.
Collins and Saitta were part of a team that detected amino acids in a titanosaur eggshell fragment, according to research published in 2024. The egg was laid by a plant-eating sauropod, a huge, long-necked dinosaur that lived in the Late Cretaceous, shortly before dinosaurs went extinct 66 million years ago.
However, the dinosaur eggshell lacked any identifiable protein sequences. Their results were akin to identifying five letters in a novel, revealing only a pattern of decay that showed there were once proteins in the eggshell, said Saitta.
'There's no sequence left, no information, just the little individual Lego building blocks of (amino acids),' Collins said.
Discover your world
Go beyond the headlines and explore the latest scientific achievements and fascinating discoveries. Sign up for CNN's Wonder Theory science newsletter. Getting protein information from a dinosaur tooth is a long shot, and Saitta noted that he had given up looking for proteins in dinosaur fossils in favor of exploring more interesting research questions.
Not only are dinosaur fossils far older than the fossils in the two studies, he noted, but they mostly date back to a hothouse period in the global climate when there were no ice caps. What's more, on average, dinosaur fossils are buried far deeper and thus have experienced far greater geothermal heat. It's also not clear whether dinosaur teeth had thick enough enamel to preserve proteins, he added.
Cappellini and Paterson said it might be possible to retrieve useful protein information from dinosaur fossils within 10 years, although there were other interesting questions to investigate first, such as how mammals came to dominate the planet after the dinosaurs' demise.
'I really think some sites might preserve dinosaur proteins in deep time. Maybe we can give those a shot,' Paterson said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
MEDIA ADVISORY: Baycrest Experts Available During AAIC® 2025 in Toronto
TORONTO, July 25, 2025 /CNW/ - From July 27 to 31, Toronto hosts the Alzheimer's Association International Conference® 2025 (AAIC®), the world's largest forum for dementia research. With Canada in the spotlight, Baycrest is recognized globally for its leadership in aging and brain health. Our scientists and experts are participating in the conference and available to support your coverage. This international gathering offers a timely opportunity to explore the growing impact of dementia on families, economies and health care systems, along with the latest advances in prevention, care, treatment and research. Dr. Howard ChertkowScientific Director, Baycrest's Kimel Family Centre for Brain Health & WellnessScientific Director, Canadian Consortium on Neurodegeneration in Aging (CCNA)Dr. Chertkow is a member of the AAIC Scientific Program Committee and one of Canada's most respected dementia researchers. He is available to speak on topics including dementia detection, prevention, treatment and Canada's role in the global research landscape. More Baycrest Experts You Can Speak With Dr. Adriana Shnall, Program Director, Baycrest Koschitzky Centre for Innovations in Caregiving, can speak to innovative tools supporting dementia caregivers, including those in rural and underserved communities. At AAIC, she is co-presenting on the use of virtual reality, AI and other strategies to better support families in community and long-term care settings. Dr. Allison Sekuler, President & Chief Scientist, Baycrest Academy for Research and Education is available to speak on the rising prevalence of dementia in Canada and its impact on individuals, families and the healthcare system. Dr. Nicole Anderson, Associate Scientific Director, Baycrest's Kimel Family Centre for Brain Health & Wellness, can discuss the latest in dementia prevention research, including evidence that nearly half of all cases may be preventable. Baycrest combines world-class care with cutting-edge research to help shape the future of aging and brain health. If you are working on AAIC-related coverage or broader dementia stories, our experts are available for interviews throughout the conference. Throughout the week, we will share updates with media highlighting key topics, research developments and expert perspectives from Baycrest. Please contact Natasha Nacevski-Laird, Media Relations Specialist at Baycrest, to schedule an interview. About Baycrest At Baycrest, our vision is a world where every older person lives with purpose, fulfilment and dignity. Baycrest is a global leader in aging and brain health innovation, with over 105 years of expertise in seniors' care and cutting-edge research. Baycrest has been Designated with Exemplary Status by Accreditation Canada, and drives industry-leading care and safety outcomes. As the home of the Centre for Aging + Brain Health Innovation (CABHI) powered by Baycrest, the Baycrest Academy for Research and Education (BARE) and the Canadian Consortium on Neurodegeneration in Aging, Baycrest is at the forefront of dementia research. Affiliated with the University of Toronto, Baycrest's training programs shape the future of care globally, while Baycrest Global Solutions extends its expertise to senior living and healthcare internationally. For more information, visit: SOURCE Baycrest View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
A science journal pulled a controversial study about a bizarre life form against the authors' wishes
NEW YORK (AP) — A microscopic discovery in a California lake sparked buzz and controversy more than a decade ago when it was first revealed. Scientists said they'd discovered bacteria that used the element arsenic — poisonous to life as we know it — to grow. If true, it expanded the possibilities for where life could exist on Earth — or on other worlds. Several research groups failed to replicate the results, and argue it's not possible for a living thing to use something so toxic to make DNA and proteins. Some scientists have suggested the results of the original experiments may have been skewed by undetected contaminants. On Thursday, the journal Science, which first published the research, retracted it, though not because of misconduct on the researchers' part. 'If the editors determine that a paper's reported experiments do not support its key conclusions, even if no fraud or manipulation occurred, a retraction is considered appropriate,' the journal's editor-in-chief Holden Thorp wrote in the statement announcing the retraction. The researchers disagree with the journal's decision and stand by their data. It's reasonable to pull a paper for major errors or suspected misconduct — but debates and disagreements over the findings are part of the scientific process, said study co-author Ariel Anbar of Arizona State University. 'One doesn't retract a paper because the interpretation is controversial, or even because most disagree with the interpretation,' wrote Anbar in an email. 'At least, that hasn't been the case until now.' Science has more frequently retracted papers for reasons beside fraud in recent years, said Thorp and Vada Vinson, Science's executive editor, wrote in a blog post. NASA helped fund the original work. The space agency's science mission chief Nicky Fox said in a statement that NASA does not support the retraction and encourages Science to reconsider. —- The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Solve the daily Crossword


Medscape
12 minutes ago
- Medscape
CATALYST: A Novel Approach to Treating Diabetes
This transcript has been edited for clarity. Akshay B. Jain, MD:Welcome, from the ADA 85th Annual Sessions in Chicago. I'm endocrinologist Akshay Jain, from University of British Columbia in Vancouver. With us today is Dr Vivian Fonseca, professor of medicine at Tulane. Welcome, Dr Fonseca. Vivian Fonseca, MD: Hi there. Thank you for asking me to join you. Jain: Dr Fonseca, you're presenting the results of the CATALYST study. Tell us a little bit more about the study. Fonseca: The CATALYST study is a very novel approach to treating diabetes. We took people with uncontrolled diabetes despite taking many medications, including insulin, GLP-1 receptor agonists, dual agonists, SGLT2 inhibitors, and metformin. They also had many medications for hypertension. We asked the question as to whether cortisol was elevated and nonsuppressed in this population. We did a very simple overnight, 1-mg dexamethasone suppression test in a little over 1000 people. We were very surprised to find that 24% of them had a cortisol that did not fully suppress. They met the criteria for hypercortisolism as recommended by the European and the US endocrine societies today, at more than 1.8. Jain: That's a staggering number. Fonseca: That is a staggering number. It was quite a surprise to me and my colleagues. Jain: Once you identify these individuals, what's the next step for them? Fonseca: For the next steps, there is a range of things to do. If you identify hypercortisolism, you want to see whether there's an adrenal tumor or something like that. We did CT scans of the abdomen in that population, and one third of them had some abnormality. Not all of them had a tumor that was surgically resectable. Some had bilateral disease, and some just had thickening, which you would just wait and watch. Here, you have a population with hypercortisolemia at a higher rate than expected, with or without an abnormality on imaging. Some of them were surgically treatable, but for this particular study, we chose to take that group of people and treat them medically. There is a wide variety of medicines available for treating elevated cortisol, which have mainly been tested in Cushing syndrome. Mifepristone is a nonspecific steroid hormone receptor blocker that's known to block cortisol action and is approved for treating hyperglycemia in people with hypercortisolism. It was okay to actually test it in this population, so we did a randomized trial, randomizing those people with hypercortisolemia in a 2:1 ratio to mifepristone or placebo and following them for 24 weeks. Jain: What were the results? Fonseca: Again, another very surprising result. The A1c fell by 1.47%, almost 1.5% from the baseline of 8.5%. That is a very, very robust response. What I like about it is that this is not giving it to everybody with diabetes. You're using what I would call precision medicine. You find an abnormality, you treat that abnormality, and you get a very good result. There were a few other spinoff things. The weight fell significantly. The waist circumference declined significantly. There were also side effects that are consistent with the mifepristone side effect profile. The potassium fell. You get hypokalemia because the cortisol levels don't fall. They rise because you're blocking the receptor and you stimulate the mineralocorticoid receptor. The blood pressure went up a little bit, but it was still mostly at goal in most of the patients. You can treat that hypokalemia, so I won't go into that. We also had what we call glucocorticoid withdrawal syndrome. People on steroids who just stop, when you treat Cushing syndrome, or any of the medications for hypercortisolemia will give you a feeling of withdrawal of the steroid that you're used to. Those are to be expected. The side effect profile shows expected side effects in many people. But still, we can get around it and get a very good result on diabetes treatment. Jain: This is fascinating. We are unmasking hypercortisolemia as an underlying reason for insulin resistance. Fonseca: I wouldn't say unmasking. We are recognizing it in a novel way for the first time, and are able to treat people who we were throwing many drugs at [the problem] — wasting those drugs, if you ask me — when we were not treating the fundamental problem. Jain: When should clinicians think about this as an underlying issue? Fonseca: The way I translate every clinical trial, you do it for what the trial was done for. You have people who are uncontrolled, or you may say difficult to control, uncontrolled or on many medications. Often, you find comorbidities. They have had this problem for a while. Many of them have complications of diabetes, and a significant number had heart disease. You treat them with a very specific treatment, and you get a good result. Now, in some people the treatment may be surgical. You could use this drug or other drugs, and there are some new ones. This has become an important target for therapy, so we will see this approach. That also leaves the question as to [the fact that] there were 24% with this abnormality. What's happening in the other 75%? Maybe there are other abnormalities that we haven't recognized. I think you and I still have a large amount of work to do. Jain: We do indeed. Your target population was individuals with type 2 diabetes. Fonseca: Type 2 diabetes that was not controlled. Jain: Do you think this could be an underlying problem in type 1 diabetes as well? Fonseca: Hypercortisolism can occur in anybody. If you're finding many challenges in type 1 diabetes, you could do it. Obviously, people who are not doing well in their general health without diabetes could have hypercortisolism. This is not what we recognize as the textbook Cushing syndrome. These people did not have those features. The obesity was mild and low central. They had little features, but not the full-blown textbook description, which comes after many years of having very severe hypercortisolism. Jain: For those individuals who, say, are on birth control, would you then recommend doing a urine test? Fonseca: That's a very important question. We excluded those people from the study because you get a false elevation due to raising cortisol-binding globulin with estrogen. We did it in people who had a probability based on some anecdotal things and studies in Europe that were done before, and also excluding people who would have a false positive or a false negative, such as [those with] estrogen use. We don't know how to really identify those people well, without stopping the therapy. Jain: Any final key pearls of wisdom from this trial? Fonseca: I think, like anything that's new, it's exciting. Many of these people were very glad that we found an abnormality. I mean, it sounds bad, but they were blaming themselves, they were being labeled as noncompliant, and they were very frustrated with this. Jain: And the medication burden that they were facing. Fonseca: We actually withdrew a number of medications on several people. Jain: Great. Those are the results of the CATALYST trial. Thank you so much, Dr Fonseca, for joining. Fonseca: Thank you. It's a pleasure to be here.